Murine mesothelioma induces locally-proliferating IL-10⁺TNF-α⁺CD206⁻CX3CR1⁺ M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy

References

• Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 2003; 171:5051-63; PMID:14607902; http://dx.doi.org/10.4049/jimmunol.171.10.5051
   PubMed Web of Science ®Google Scholar
• Jackaman C, Cornwall S, Graham PT, Nelson DJ. CD40-activated B cells contribute to mesothelioma tumor regression. Immunol Cell Biol 2011; 89:255-67; PMID:20628372; http://dx.doi.org/10.1038/icb.2010.88
   PubMed Web of Science ®Google Scholar
• Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, Robinson BW, Nelson DJ. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 2008; 20:1467-79; PMID:18824504; http://dx.doi.org/10.1093/intimm/dxn104
   PubMed Web of Science ®Google Scholar
• Jackaman C, Nelson DJ. Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution. Cancer Gene Ther 2010; 17:429-40; PMID:20150930; http://dx.doi.org/10.1038/cgt.2009.85
   PubMed Web of Science ®Google Scholar
• Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Scott B, Robinson BW. Interleukin-12 induces an effective antitumor response in malignant mesothelioma. Am J Respir Cell Mol Biol 1998; 19:738-46; PMID:9806738; http://dx.doi.org/10.1165/ajrcmb.19.5.3257m
   PubMed Web of Science ®Google Scholar
• Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 2012; 13:e301-10; PMID:22748269; http://dx.doi.org/10.1016/S1470-2045(12)70126-2
   PubMed Web of Science ®Google Scholar
• Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 1999; 59:1071-9; PMID:10070965
   PubMed Web of Science ®Google Scholar
• Robinson BW, Scott BM, Lake RA, Stumbles PA, Nelson DJ, Fisher S, Marzo AL. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis–implications for tumor tolerance. Clin Cancer Res 2001; 7:811s-7s; PMID:11300477
   PubMedGoogle Scholar
• Vachani A, Sterman DH, Albelda SM. Cytokine gene therapy for malignant pleural mesothelioma. J Thorac Oncol 2007; 2:265-7; PMID:17409795; http://dx.doi.org/10.1097/01.JTO.0000263706.23579.35
   PubMed Web of Science ®Google Scholar
• Jackaman C, Cornwall S, Lew AM, Zhan Y, Robinson BW, Nelson DJ. Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells. Eur Respir J 2009; 34:162-75; http://dx.doi.org/10.1183/09031936.00101008
   PubMed Web of Science ®Google Scholar
• Jackaman C, Cornwall S, Lew AM, Zhan Y, Robinson BW, Nelson DJ. Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells. Eur Respir J 2009; 34:162-75; PMID:19251786; http://dx.doi.org/10.1183/09031936.00101008
   PubMed Web of Science ®Google Scholar
• Burt BM, Rodig SJ, Tilleman TR, Elbardissi AW, Bueno R, Sugarbaker DJ. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 2011; 117:5234-44; PMID:21523763; http://dx.doi.org/10.1002/cncr.26143
   PubMed Web of Science ®Google Scholar
• Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008; 13:453-61; PMID:17981560; http://dx.doi.org/10.2741/2692
   PubMed Web of Science ®Google Scholar
• Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A, Gherardi RK, Chazaud B. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med 2007; 204:1057-69; PMID:17485518; http://dx.doi.org/10.1084/jem.20070075
   PubMed Web of Science ®Google Scholar
• Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, Norwood C, Wang E, Marincola FM, Stroncek DF. Gene expression profiling of cutaneous wound healing. J Transl Med 2007; 5:11; PMID:17313672; http://dx.doi.org/10.1186/1479-5876-5-11
   PubMed Web of Science ®Google Scholar
• Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006; 107:2112-22; PMID:16269622; http://dx.doi.org/10.1182/blood-2005-01-0428
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:549-55; PMID:12401408; http://dx.doi.org/10.1016/S1471-4906(02)02302-5
   PubMed Web of Science ®Google Scholar
• Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, Bottazzi B, Colombo MP, Mantovani A, Sica A. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 2006; 66:11432-40; PMID:17145890; http://dx.doi.org/10.1158/0008-5472.CAN-06-1867
   PubMed Web of Science ®Google Scholar
• Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179:977-83; PMID:17617589; http://dx.doi.org/10.4049/jimmunol.179.2.977
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
   PubMed Web of Science ®Google Scholar
• Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6:409-21; PMID:15488763; http://dx.doi.org/10.1016/j.ccr.2004.08.031
   PubMed Web of Science ®Google Scholar
• Pelegrin P, Surprenant A. Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates. EMBO J 2009; 28:2114-27; PMID:19536133; http://dx.doi.org/10.1038/emboj.2009.163
   PubMed Web of Science ®Google Scholar
• Miselis NR, Wu ZJ, Van Rooijen N, Kane AB. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 2008; 7:788-99; PMID:18375821; http://dx.doi.org/10.1158/1535-7163.MCT-07-0579
   PubMed Web of Science ®Google Scholar
• Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 2010; 10:464; PMID:20804550; http://dx.doi.org/10.1186/1471-2407-10-464
   PubMed Web of Science ®Google Scholar
• Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331:1612-6; PMID:21436454; http://dx.doi.org/10.1126/science.1198443
   PubMed Web of Science ®Google Scholar
• Jackaman C, Radley-Crabb HG, Soffe Z, Shavlakadze T, Grounds MD, Nelson DJ. Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice. Aging Cell 2013; 12:345-57; PMID:23442123; http://dx.doi.org/10.1111/acel.12062
   PubMed Web of Science ®Google Scholar
• Jackaman C, Dye DE, Nelson DJ. IL-2/CD40-activated macrophages rescue age and tumor-induced T cell dysfunction in elderly mice. Age (Dordr) 2014; 36:9655; PMID:24744051; http://dx.doi.org/10.1007/s11357-014-9655-y
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11:6713-21; PMID:16166452; http://dx.doi.org/10.1158/1078-0432.CCR-05-0883
   PubMed Web of Science ®Google Scholar
• Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008; 66:1-9; PMID:17913510; http://dx.doi.org/10.1016/j.critrevonc.2007.07.004
   PubMed Web of Science ®Google Scholar
• Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K, Gordon S, Balkwill FR. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 2006; 176:5023-32; PMID:16585599; http://dx.doi.org/10.4049/jimmunol.176.8.5023
   PubMed Web of Science ®Google Scholar
• Bedoret D, Wallemacq H, Marichal T, Desmet C, Quesada Calvo F, Henry E, Closset R, Dewals B, Thielen C, Gustin P et al. Lung interstitial macrophages alter dendritic cell functions to prevent airway allergy in mice. J Clin Invest 2009; 119:3723-38; PMID:19907079; http://dx.doi.org/10.1172/JCI39717
   PubMed Web of Science ®Google Scholar
• Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70:5728-39; PMID:20570887; http://dx.doi.org/10.1158/0008-5472.CAN-09-4672
   PubMed Web of Science ®Google Scholar
• Tsai CS, Chen FH, Wang CC, Huang HL, Jung SM, Wu CJ, Lee CC, McBride WH, Chiang CS, Hong JH. Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys 2007; 68:499-507; PMID:17398016; http://dx.doi.org/10.1016/j.ijrobp.2007.01.041
   PubMed Web of Science ®Google Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141:39-51; PMID:20371344; http://dx.doi.org/10.1016/j.cell.2010.03.014
   PubMed Web of Science ®Google Scholar
• Buhtoiarov IN, Lum H, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol 2005; 174:6013-22; PMID:15879094; http://dx.doi.org/10.4049/jimmunol.174.10.6013
   PubMed Web of Science ®Google Scholar
• Economou JS, McBride WH, Essner R, Rhoades K, Golub S, Holmes EC, Morton DL. Tumour necrosis factor production by IL-2-activated macrophages in vitro and in vivo. Immunology 1989; 67:514-9; PMID:2788610
   PubMed Web of Science ®Google Scholar
• Puddu P, Carollo M, Pietraforte I, Spadaro F, Tombesi M, Ramoni C, Belardelli F, Gessani S. IL-2 induces expression and secretion of IFN-gamma in murine peritoneal macrophages. J Leukoc Biol 2005; 78:686-95; PMID:15951352; http://dx.doi.org/10.1189/jlb.0105035
   PubMed Web of Science ®Google Scholar
• Jackaman C, Nelson DJ. Intratumoral interleukin-2/agonist CD40 antibody drives CD4(+)-independent resolution of treated-tumors and CD4 (+)-dependent systemic and memory responses. Cancer Immunol Immunother 2011; 61(4):549-60; PMID:22002241; http://dx.doi.org/10.1007/s00262-011-1120-5
   PubMed Web of Science ®Google Scholar
• Austyn JM, Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 1981; 11:805-15; PMID:7308288; http://dx.doi.org/10.1002/eji.1830111013
   PubMed Web of Science ®Google Scholar
• Gordon S, Hamann J, Lin H-H, Stacey M. F4/80 and the related adhesion-GPCRs. Eur J Immunol 2011; 41:2472-6; PMID:21952799; http://dx.doi.org/10.1002/eji.201141715
   PubMed Web of Science ®Google Scholar
• Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer 2012; 12:35; PMID:22273460; http://dx.doi.org/10.1186/1471-2407-12-35
   PubMed Web of Science ®Google Scholar
• Zaynagetdinov R, Sherrill TP, Polosukhin VV, Han W, Ausborn JA, McLoed AG, McMahon FB, Gleaves LA, Degryse AL, Stathopoulos GT et al. A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J Immunol 2011; 187:5703-11; PMID:22048774; http://dx.doi.org/10.4049/jimmunol.1100558
   PubMed Web of Science ®Google Scholar
• Kim SW, Kim JS, Papadopoulos J, Choi HJ, He J, Maya M, Langley RR, Fan D, Fidler IJ, Kim SJ. Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse. Int Immunopharmacol 2011; 11:862-72; PMID:21251905; http://dx.doi.org/10.1016/j.intimp.2011.01.004
   PubMed Web of Science ®Google Scholar
• Fritz JM, Tennis MA, Orlicky DJ, Lin H, Ju C, Redente EF, Choo KS, Staab TA, Bouchard RJ, Merrick DT et al. Depletion of tumor-associated macrophages slows the growth of chemically induced mouse lung adenocarcinomas. Front Immunol 2014; 5:587; PMID:25505466; http://dx.doi.org/10.3389/fimmu.2014.00587
   PubMed Web of Science ®Google Scholar
• Kruse J, von Bernstorff W, Evert K, Albers N, Hadlich S, Hagemann S, Günther C, van Rooijen N, Heidecke CD, Partecke LI. Macrophages promote tumour growth and liver metastasis in an orthotopic syngeneic mouse model of colon cancer. Int J Colorectal Dis 2013; 28:1337-49; PMID:23657400; http://dx.doi.org/10.1007/s00384-013-1703-z
   PubMed Web of Science ®Google Scholar
• Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, Franzoso G, Lotze MT, Krausz T, Pass HI et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A 2010; 107:12611-6; PMID:20616036; http://dx.doi.org/10.1073/pnas.1006542107
   PubMed Web of Science ®Google Scholar
• Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev 1997; 6:162-6; PMID:9237066
   PubMed Web of Science ®Google Scholar
• Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR. “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008; 205:1261-8; PMID:18490490; http://dx.doi.org/10.1084/jem.20080108
   PubMed Web of Science ®Google Scholar
• Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7:211-7; PMID:15766659; http://dx.doi.org/10.1016/j.ccr.2005.02.013
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; PMID:12490959; http://dx.doi.org/10.1038/nature01322
   PubMed Web of Science ®Google Scholar
• Edwards JG, Faux SP, Plummer SM, Abrams KR, Walker RA, Waller DA, O'Byrne KJ. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002; 8:1857-62; PMID:12060628
   PubMed Web of Science ®Google Scholar
• Demetri GD, Zenzie BW, Rheinwald JG, Griffin JD. Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood 1989; 74:940-6; PMID:2787682
   PubMed Web of Science ®Google Scholar
• Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF β expression. J Pathol 1999; 189:72-8; PMID:10451491; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c72::AID-PATH401%3e3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499-506; PMID:19342621; http://dx.doi.org/10.4049/jimmunol.0802740
   PubMed Web of Science ®Google Scholar
• Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66:1123-31; PMID:16424049; http://dx.doi.org/10.1158/0008-5472.CAN-05-1299
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13:828-35; PMID:17603493; http://dx.doi.org/10.1038/nm1609
   PubMed Web of Science ®Google Scholar
• Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res 2015; 128:95-139; PMID:26216631; http://dx.doi.org/10.1016/bs.acr.2015.04.002
   PubMed Web of Science ®Google Scholar
• Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 2015; 125:3356-64; PMID:26168215; http://dx.doi.org/10.1172/JCI80005
   PubMed Web of Science ®Google Scholar
• Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 2013; 39:611-21; PMID:24012420; http://dx.doi.org/10.1016/j.immuni.2013.08.025
   PubMed Web of Science ®Google Scholar
• Zheng J, Yang M, Shao J, Miao Y, Han J, Du J. Chemokine receptor CX3CR1 contributes to macrophage survival in tumor metastasis. Mol Cancer 2013; 12:141; PMID:24245985; http://dx.doi.org/10.1186/1476-4598-12-141
   PubMed Web of Science ®Google Scholar
• Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009; 9:900-9; PMID:19336265; http://dx.doi.org/10.1016/j.intimp.2009.03.015
   PubMed Web of Science ®Google Scholar
• Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63:4490-6; PMID:12907622
   PubMed Web of Science ®Google Scholar
• Broomfield S, Currie A, van der Most RG, Brown M, van Bruggen I, Robinson BW, Lake RA. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 2005; 65:7580-4; PMID:16140921; http://dx.doi.org/10.1158/0008-5472.CAN-05-0328
   PubMed Web of Science ®Google Scholar
• Parker KH, Sinha P, Horn LA, Clements VK, Yang H, Li J, Tracey KJ, Ostrand-Rosenberg S. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res 2014; 74:5723-33; PMID:25164013; http://dx.doi.org/10.1158/0008-5472.CAN-13-2347
   PubMed Web of Science ®Google Scholar